This is a repository copy of Effect of tocilizumab therapy on il-6 signalling pathway in early rheumatoid arthritis patients.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/132036/

Version: Accepted Version

Proceedings Paper:

https://doi.org/10.1136/annrheumdis-2016-211049.24

© 2017, Published by the BMJ Publishing Group Limited. This is an author produced version of a paper published in Annals of the Rheumatic Diseases. Uploaded in accordance with the publisher's self-archiving policy.

Reuse
Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
EFFECT OF TOCILIZUMAB THERAPY ON IL-6 SIGNALLING PATHWAY IN EARLY RHEUMATOID ARTHRITIS PATIENTS

Lylia Ouboussad1,2, Chi Wong1,2, Laura Hunt1,2, Paul Emery1,2, Michael F. McDermott1,2, Aamir Aslam1,2, Maya H. Buch1,2

1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; 2NIHR-Leeds Musculoskeletal Biomedical Research Unit (NIHR-LMBRU), Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds, UK.

Background and objectives
We previously reported increased constitutive but unchanged induced CD4+ p-STAT3 in established RA versus healthy control (HC) (1).

This study aims to evaluate in early RA (ERA) (i) cell-subset constitutive and Cis (IL-6) and Trans (IL-6/sIL6R)-induced IL-6 signalling (ii) effect of tocilizumab (TCZ; +/-MTX) (iii) for an association between baseline phosphorylation intensities and TCZ (+/- MTX) response.

Materials and methods
Multiparameter phosphoflow cytometry was performed on 20 treatment-naïve, ERA patients randomised to TCZ monotherapy or TCZ-MTX to determine STAT3, Akt and Erk phosphorylation intensities. PBMCs were isolated and cryopreserved at baseline, and weeks 24 and 48 post-TCZ. HC samples (n=10) were also obtained. PBMCs were unmodulated, stimulated with IL-6 or soluble IL-6 receptor (sIL-6R) and median fluorescence intensities (MFI) were measured.

Results
Baseline data, HC & ERA
Constitutive CD4+ p-STAT3 was numerically higher in ERA compared to HC, with non-significant increase following stimulation in both groups.
There was no significant difference in constitutive monocyte p-STAT3 in HC vs ERA. Stimulation did not induce further increase in monocyte p-STAT3 in ERA.
Constitutive CD4+ p-Akt was significantly higher in ERA versus HC (p=0.01), with no change post-stimulation.

Pre/Post TCZ in ERA
Constitutive CD4+ pSTAT3 expression did not alter following TCZ exposure. Statistically significant decreases in IL-6 stimulated CD4+ pSTAT3 expression from baseline to weeks 24 and 48 were observed (p=0.005 and 0.01 respectively); and similarly using IL-6/sIL-6R at week 48 (p=0.01).
Constitutive monocyte p-STAT3 expression appeared to increase at week 24 compared to baseline (p=0.03); similar observation following stimulation with IL-6/sIL-6R at both weeks 24 and 48 was observed (p=0.01).

TCZ led to non-significant decrease in constitutive and IL6-stimulated CD4+ p-Akt expression weeks 24 and 48. TCZ otherwise had no significant effect on p-Akt and p-Erk in other studied cell subsets.

**Conclusions**
TCZ reduced induced IL-6 signalling via CD4+ STAT3. This preliminary analysis also suggests importance of monocyte subset and relevance of Akt in IL-6 signalling. Complete analysis of these data will clarify the relative roles and impact of IL-6R targeting further.

**References**